Hepatocellular carcinoma review: Current treatment, and evidence-based medicine

Table 2 Phase III clinical trials of systemic targeted agents

Ref.	Year	Patients (n)	Overall survival (mo)
Llovet et al[82]	2008	Sorafenib: 299	Sorafenib: 10.7
(SHARP trial)		Placebo: 303	Placebo: 7.9
Cheng et al[83]	2009	Sorafenib: 150	Sorafenib: 6.5
(NCT00492752)		Placebo: 76	Placebo: 4.2
Zhu et al[100]	2012	Sorafenib: 358	Sorafenib: 8.5
(SEARCH trial)		Sorafenib +	Sorafenib +
		Erlotinib: 362	Erlotinib: 9.5
Cheng et al[99]	2013	Sorafenib: 544	Sorafenib: 10.2
(SUN1170 trial)		Sunitinib: 530	Sunitinib: 7.9
Cainap et al[101]	2013	Sorafenib: N/A	Sorafenib: 9.8
(LIGHT trial)		Linifanib: N/A	Linifanib: 9.1
Johnson et al[95]	2013	Sorafenib: 578	Sorafenib: 9.9
(BRISK-FL trial)		Brivanib: 577	Brivanib: 9.5
Llovet et al[94]	2013	Brivanib: 263	Brivanib: 9.4
(BRISK-PS trial)		Placebo: 132	Placebo: 8.3